What Clatra Treats: Main Uses and Benefits

Clatra is commonly used for managing symptoms related to inflammatory or irritative states, which may provide support that contributes to easing the overall symptom load. The primary therapeutic contexts are aligned with domains involving significant symptom expression.

---

The medication is relevant in conditions characterized by periods of heightened symptoms associated with nasal and ocular allergies, including both seasonal and perennial allergic rhinitis. It is also applied in clinical settings that involve acute or unstable symptom patterns from urticaria (hives) and Chronic Spontaneous Urticaria (CSU).

Clatra helps address symptom clusters that may become disruptive, such as frequent sneezing, runny nose, itchy eyes, and the pronounced pruritus (skin itching) linked to hives. This focus on symptomatic relief is essential, as:

“The primary goal is to help patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability during symptomatic periods.”

Clatra supports symptomatic relief in contexts involving heightened systemic burden and is generally applied as a non-sedating option. This is relevant when supportive symptom management is appropriate for adults, adolescents, and children who need to remain active.

Quick Fact: Relief for Disruptive Symptoms

Symptom Domain	Key Symptoms Addressed
Allergic Rhinitis	Sneezing, nasal itching, runny nose, nasal congestion
Urticaria	Skin itching (pruritus), wheals (hives), redness (erythema)

Who can and cannot use Clatra

Clatra (bilastine) eligibility is determined by specific regulatory rules regarding age, pre-existing conditions, and physiological status.

Absolute Contraindications The medicine must not be used by individuals with a hypersensitivity (allergy) to bilastine or any component of the formulation. Use is also contraindicated in patients with a history of QT prolongation or related conditions, including congenital long QT syndromes.

---

Age-Group Eligibility Clatra is approved for Adults and Adolescents 12 years and older. It is also indicated for Children 6 to 11 years of age with a minimum body weight of 20 kilograms. Safety and efficacy are not established for children under 6 years or those weighing less than 20 kg.

---

Restrictions in Specific Populations

Population Group	Regulatory Status
Pregnancy	Preferably avoided (due to limited human data)
Lactation	Excretion into human milk not studied
Organ Impairment	No adjustment needed for standard hepatic or renal impairment in adults

A strict caution applies to patients with moderate or severe renal impairment: they should avoid co-administration with certain other medicines (P-glycoprotein inhibitors) to prevent elevated drug levels.

Clatra (bilastine) has documented interactions that primarily involve drug transporter systems, as it is not significantly metabolized by the Cytochrome P450 (CYP) enzyme system. This minimal metabolic profile limits its potential for conventional drug-drug interactions involving the CYP pathway.

The most relevant pharmacokinetic interactions involve the P-glycoprotein ( P-gp) transporter, for which bilastine is a substrate. Co-administration with strong P-gp inhibitors—including medicines such as ketoconazole, erythromycin, diltiazem, and cyclosporine—may result in a significant increase in the systemic exposure ( AUC) of bilastine. Official regulatory documentation advises caution or avoidance with these agents.

Food and Juice Interactions

Administration with food or fruit juices, especially grapefruit juice, has been shown to reduce the oral bioavailability of bilastine. This effect is attributed to the interaction of the juice components with intestinal transporters, leading to less of the drug being absorbed. Regulatory instructions therefore stipulate that this medicine must be taken on an empty stomach, either one hour before a meal or two hours after eating or drinking fruit juice.

Pharmacodynamic (PD) Interaction Risk

There is a potential for an additive effect when bilastine is co-administered with other medicinal products known to prolong the QT interval. This requires that health professionals exercise particular care and enhanced monitoring when prescribing bilastine alongside QT-prolonging drugs.

Clatra (bilastine) works by engaging specific mechanistic domains to modulate the body’s response to signaling molecules, initiating a cascade that influences localized physiological responses.

---

Selective H1 Receptor Antagonism

This core mechanistic domain involves Clatra's action as a selective inverse agonist at the peripheral H1 histamine receptor. By binding to this receptor, the drug suppresses its activity, which in turn blocks the intracellular signaling cascade normally initiated by histamine—a key mediator in various physiological responses.

---

Modulation of Mediator Cascade

Clatra's engagement with the H1 receptor modifies the early molecular steps that drive the body’s physiological response. This action reduces the downstream cascade of mediator release, resulting in a modulation of mediator activity within targeted tissues and a modification of systemic physiological outcomes.

---

Central Nervous System Engagement Profile

Clatra exhibits low penetration of the blood-brain barrier and minimal affinity for muscarinic receptors. This profile ensures that mechanistic effects are primarily focused on peripheral pathways, minimizing central nervous system involvement.

The administration of Clatra (bilastine) is strictly based on the oral route using fixed-dose, once-daily regimens.

Official Dosing and Forms

Feature	Adult and Adolescent (ge 12 years)	Pediatric (6 to 11 years, ge 20 kg)
Dose	20 mg	10 mg
Frequency	Once daily	Once daily
Form	Tablet (20 mg)	ODT or Oral Solution (10 mg dose)

Administration is generally limited to the period of symptom manifestation, such as during seasonal allergen exposure, or for a variable duration as determined by the nature and course of chronic symptoms. The maximum daily dose for adults and adolescents is 20 mg and should not be exceeded. If a dose is missed, patients should take the next scheduled dose as usual and must not take a double dose to compensate.

Administration Conditions

Clatra must be taken on an empty stomach to ensure optimal exposure to the active substance (bilastine). This typically means taking the dose one hour before food or two hours after consuming any food or fruit juice. The medicine should not be taken with grapefruit or any other fruit juices, as these beverages can reduce the drug’s effectiveness. The tablet is swallowed with water, while the orodispersible tablet can be rapidly dispersed in water for swallowing.

No dosage adjustment is required for older adults or for patients with renal or hepatic impairment, as bilastine is minimally metabolized and largely excreted unchanged. Use is not recommended for children under 6 years of age.

Research Evidence: Overview of Studies for Clatra

This overview summarizes the type of formal clinical research and scientific reviews that have been conducted for the medication Clatra (bilastine), focusing only on the structure of the evidence used by regulatory bodies. It describes what the studies examined, what findings were observed, and where limitations or research gaps exist, consistent with scientific sources.

---

Evidence for Symptomatic Management of Allergic Rhinitis

Research exploring how symptoms change over time in patients with allergic rhinitis has mainly used short-term randomized controlled trials (RCTs). The primary outcomes evaluated were patient-reported experiences, particularly focusing on the Total Symptom Score (TSS), a combined measure of nasal and eye symptoms. These studies predominantly included adults and adolescents (≥ 12 years). The findings describe patterns observed in the studies over these short, defined time intervals. This research describes short-term changes in these conditions characterized by fluctuating or episodic manifestations.

Evidence is limited regarding the maintenance of these measured outcomes over very long periods. Follow-up durations were limited in the primary efficacy trials, which typically lasted only 14 days. While some longer-term safety research exists, there is limited information for sustained outcomes related to year-round perennial allergic rhinitis based on large, controlled studies.

---

Evidence for Symptomatic Management of Chronic Spontaneous Urticaria (Hives)

Clatra was evaluated in studies examining symptom intensity or variability in conditions involving periods of heightened symptoms such as chronic spontaneous urticaria (hives). Studies monitored outcomes linked to inflammatory or irritative states, focusing specifically on the severity of itching (pruritus) and the count and size of wheals (hives), often combined into the Weekly Urticaria Activity Score (UAS-7). Data show patterns related to how symptoms evolved, focusing on the UAS-7 scores over trial periods that commonly lasted around four weeks.

Comparative evidence is primarily against a limited set of similar medications. Studies exploring higher than standard doses often rely on observational settings or have limited controlled comparative data. Furthermore, long-term effects are not fully established regarding the sustained management of symptoms for patients facing years of recurrent urticaria flares.

---

Areas of Research Uncertainty and Study Gaps

The major limitation across all indications is the limited information for long-term outcomes from placebo-controlled trials. The results apply primarily to the populations studied in the short-term, acute settings. Follow-up durations were limited in the pivotal efficacy trials, meaning long-term symptomatic patterns are not well characterized. Furthermore, comparative evidence is lacking across a wider range of similar medications.

Key Studies & References Efficacy of bilastine in seasonal allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials

Common questions about Clatra (FAQ)

---

Q: How long does it take for Clatra to start working after I take it?

Official studies show that the maximum concentration of the active ingredient, bilastine, in the bloodstream is typically reached in approximately 1.3 hours after administration. This measurement, known as time to peak concentration, is a marker that indicates when the active substance is maximally present in the bloodstream.

---

Q: Can I take Clatra if I have kidney (renal) or liver (hepatic) problems?

Official product information generally indicates that no dose adjustment is required for patients with standard liver or kidney impairment. However, for those with moderate to severe kidney impairment, co-administration of this medicine with certain P-glycoprotein inhibitor medications (such as ketoconazole or erythromycin) should be avoided, as this may increase the concentration of the drug.

---

Q: Are there any warnings about taking Clatra with heart conditions?

Regulatory documents indicate that the medicine is contraindicated (should not be used) in patients with a history of QT prolongation. Caution is advised for patients who have existing risk factors for QTc interval prolongation or who are taking other medications known to affect this cardiac interval.

---

Q: Is Clatra safe to take while pregnant or breastfeeding?

Due to limited data on its use in humans, regulatory documents state that use during pregnancy is preferably avoided as a precautionary measure. It is not known if the active ingredient is passed into human milk during lactation. A clinical decision on its use must consider the risks and benefits in this context.

---

Q: What should I do if my child accidentally takes too much Clatra?

In cases of overdose, official product information suggests that symptomatic and supportive measures may be appropriate. Monitoring of the heart’s electrical activity, specifically an electrocardiogram ( ECG), is also recommended following an overdose.

---

Q: What are the ingredients in Clatra besides Bilastine?

Clatra contains the active ingredient, bilastine, along with various inactive ingredients known as excipients. The complete list of these excipients for the specific dosage form you are using (tablet, oral solution, etc.) is listed in the official Summary of Product Characteristics ( SmPC) for the product.

Storage and Disposal Requirements for Clatra (Bilastine)

The official storage and disposal requirements for Clatra are designed to maintain product integrity and ensure environmental safety, based on government regulatory labeling.

Storage Conditions

Requirement	Official Instruction
Temperature	Generally, no special storage conditions are required.
Protection	Store in the original package and do not use after the expiry date (EXP).
Child Safety	The medicine must be kept strictly out of the sight and reach of children.

Disposal

All unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste. It is explicitly stated that the medicine must not be thrown away via wastewater or household waste to protect the environment.